All posts by imreal

Integrated Perspectives for Enhanced Rare Disease Drug Development, Upcoming Webinar Hosted by Xtalks


Learn how a patient-first approach can be implemented through all stages of therapy development.

When rare is not so rare; more than 400 million people globally are affected by 10,000 distinct rare diseases. Despite increasing awareness of, and action to address these populations, 95 percent of all rare diseases do not have a single US Food and Drug Administration (FDA)-approved rare disease drug treatment.

New Medicines, Novel Insights is Parexel’s perspective on bringing life-changing medicines to market. The inaugural report, launching on Rare Disease Day (28 February 2023), explores the nuances that are key to rare disease drug development success.

Join this webinar for an overview of the highlights contained within the report, with a focus on the four key perspectives required to bring a new therapeutic to market: patients, clinical development, regulatory strategy and market access.

Learn how a patient-first approach can be implemented through all stages of therapy development. From adaptive trial design to the role of patient advocacy groups and evidence provision for payer engagement, hear from Parexel’s experts — informed by sponsor, site and patient partners — with actionable insight and real-life examples to consider for rare disease therapy development.

Join experts from Parexel, Alberto Grignolo (moderator), PhD, CVP, Corporate Strategy & Thought Leadership; Mwango Kashoki, MD MPH, Senior Vice President, Regulatory Affairs; Rachel Smith, Executive Director, Rare Disease Center of Excellence; and Wyatt Gotbetter, Senior VP/ Head, Access Consulting, for the live webinar on Thursday, March 9, 2023, at 11am EST (4pm GMT).

For more information, or to register for this event, visit Integrated Perspectives for Enhanced Rare Disease Drug Development.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

What You Need to Take Away, Upcoming Webinar Hosted by Xtalks


Join the webinar for an insightful recap of what happened at Rare Disease Day events this year!

Rare Disease Day on 28 February — and the events surrounding it — offer many exciting opportunities to raise awareness of rare diseases and reinvigorate progress for the rare disease patient communities. Events, meetings and discussions are held around the world to connect rare disease stakeholders and discuss how to support and advance treatment options together.

In this webinar, Worldwide Clinical Trials will lead a discussion panel of patient advocates active in the 2023 events surrounding Rare Disease Day. These advocates will be sharing their experiences from the past year, discussing the key discussion points that resonated with them at Rare Disease Day events this year, and their thoughts for what will come in 2023. They will also be providing their perspectives on how the clinical development industry can create better clinical trials, treatment options and more accessible and inclusive trials.

Leading up to the webinar, follow the hashtag #RareDiseaseDayWrapped on LinkedIn for live posts from the panelists, hosts and rare community about what is going on in the events surrounding Rare Disease Day.

Join the webinar for an insightful recap of what happened at Rare Disease Day events this year!

Join Rob Long, Executive Director, Uplifting Athletes; Richie Kahn, MPH, Co-Founder and Principal, Canary Advisors; Jenn McNary, Co-Founder and Principal, Canary Advisors; Kyle Bryant, Director of rideATAXIA, Friedreich’s Ataxia Research Alliance (FARA); Christine Waggoner, President & Founder, Cure GM1 Foundation; and hosts Derek Ansel, MS, CCRA, Executive Director, Therapeutic Strategy Lead, Rare Diseases, Worldwide Clinical Trials; and Amy Raymond, PhD, PMP, Senior Director, Therapeutic Strategy Lead, Rare Diseases, Worldwide Clinical Trials, for the live webinar on Tuesday, March 7, 2023, at 3pm EST (12pm PST).

For more information, or to register for this event, visit Rare Disease Day 2023 Wrapped: What You Need to Take Away.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Patent Analytics — Maximizing Value in Freedom to Operate and Landscapes, Upcoming Webinar Hosted by Xtalks


A good practitioner will want to know what they can find using standard patent analytics tools, a little cleverness and the willingness to get their hands dirty with the data.

Patent search and research reports are valuable tools for any Intellectual Property (IP) practitioner, but they’re not the only tool for finding actionable insights from patent data. A good practitioner will want to know what they can find using standard patent analytics tools, a little cleverness and the willingness to get their hands dirty with the data.

This webinar will cover what to do after receiving an Freedom to Operate (FTO) or landscape report, and how to use the data and analyses in that report to learn even more insights and keep them up to date for months and years afterwards. The featured speaker will discuss creating ongoing alerts and searches, using patent data and metadata to investigate competitors and find filing trends and patterns, custom analytics to look “ahead” of the publicly available data and AI-driven search and analysis tools to find patents and non-patent literature (NPL) that will escape a traditional keyword search. Above all, the speaker will discuss using time- and cost-effective methods that will allow attendees to not only use patent reports but get more out of them.

Register today and learn more about maximizing the value of patent analytics in FTO and landscapes.

Join Chris Huffines, Manager – Search Services, Client Growth, PatSnap, for the live webinar on Wednesday, March 8, 2023, at 11am EST (4pm GMT/UK).

For more information, or to register for this event, visit Patent Analytics — Maximizing Value in Freedom to Operate and Landscapes.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Arizona Dispensaries Association Partners with Arizona Poison Centers to Promote Safe Cannabis Use, Informational Resources


“We aim to continuously educate consumers on the importance of visiting only licensed dispensaries and consuming only THC and CBD products that have been lab tested and approved,” said Ann Torrez, Arizona Dispensaries Association executive director.

Arizona Dispensaries Association (ADA), the voice of Arizona’s cannabis industry, and Arizona Poison Centers have created a partnership which includes an awareness campaign about cannabis product safety in the home.

Arizona Poison Centers saw 739 cases of cannabis-related incidents in 2022, over half of which involved children. Of the 394 pediatric cases, 60% involved a hospital visit.

“With more cannabis products available and in the home, there is an increased likelihood of children becoming exposed” stated Maureen Roland, RN, Managing Director at Banner Poison and Drug Information Center. “The Arizona Poison Centers are working with the ADA to improve public knowledge and awareness regarding this emerging concern and educate consumers on how to prevent these incidents from occurring.”

“Much like medications or alcohol, what can be safely used by an adult can be very problematic for children,” said Steve Dudley, PharmD, DABAT, Director of the Arizona Poison and Drug Information Center. “Thankfully we know that with proper education and safe storage we can dramatically reduce these exposures and hospitalizations.” Dr. Dudley also added “We must do a better job at distinguishing toxicity from regulated products purchased at dispensaries and unregulated products from the black-market including spice and delta-8 THC.”

“The ADA’s primary mission is to promote and advocate for a safe, consumer-focused cannabis industry in Arizona,” said Ann Torrez, Arizona Dispensaries Association executive director. “We aim to continuously educate consumers on the importance of visiting only licensed dispensaries and consuming only THC and CBD products that have been lab tested and approved. We’re working with Arizona Poison Centers to educate Arizonans on steps to take in case of accidental ingestion by children, or what to watch out for in adults who are having an adverse reaction to a product.”

ADA is providing window clings to its member dispensaries across the state that include a QR code guiding consumers to the ADA website with a link to education and information regarding safe and responsible cannabis usage on the ADA website.

The ADA is actively working with the Arizona Department of Health and legislators to align statutes and rules to ensure that all marijuana products are not attractive to children and are placed in child-resistant packaging on exit.

All ADA members are Arizona Department of Health-licensed medical marijuana dispensaries and adult use establishments. All employees within these businesses are authorized by AZDHS to work in the industry. Consumers shopping at ADA member dispensaries can feel confident that they are purchasing legal products that are third-party laboratory tested, including testing for pesticides, microbials and cannabinoids.

To find out more, visit the Arizona Dispensaries Association website.

For more resources and information from the Arizona Poison Centers, please visit https://azpoison.com/ or https://www.bannerhealth.com/services/poison-drug-information

About Arizona Dispensaries Association

The Arizona Dispensaries Association (ADA) is the voice of Arizona’s cannabis industry. ADA is dedicated to advancing the Arizona cannabis industry through political advocacy, public education, and professionalization. Our mission is to promote and advocate for a safe, consumer-focused cannabis industry in Arizona. We develop best practices and effectively represent the industry with a constant legislative and regulatory presence. Our practice is to recruit and retain responsible industry members who believe in protecting consumers and providing high quality cannabis in Arizona.

About the Arizona Poison Centers

The poison and drug information centers at the University of Arizona College of Pharmacy in Tucson and at Banner – University Medical Center Phoenix provide free and confidential poison control and medication information to the public and healthcare professionals. The hotlines operate 24 hours a day, seven days a week. The two centers serve all of Arizona and are part of 55 centers across the nation that are accredited by the American Association of Poison Control Centers. Call (800) 222-1222 from any location to reach the poison center nearest you.

Share article on social media or email:

Proscia Builds Momentum In Life Sciences Market Led By Customer And Product Growth


News Image

Beyond powering R&D at scale today, Concentriq for Research will enable research teams to capitalize on new opportunities that reimagine the potential of pathology data in advancing how we treat patients for years to come. -David West, CEO of Proscia.

Proscia®, a leading provider of digital and computational pathology solutions, has achieved new milestones that strengthen its leadership position in the life sciences market. The company now counts 14 of the top 20 pharmaceutical companies among its users. This growth comes as Proscia continues to help users realize the full promise of their pathology data with updates to its flagship Concentriq® for Research software platform, robust developer tools, and an enhanced customer experience.

Pathology data shapes the discovery and development of every drug brought to market. With Concentriq for Research, Proscia has established the digital pathology platform as a key driver of data-driven innovation across R&D. Leading pharmaceutical companies, contract research organizations, and emerging biotechs rely on the platform to power diverse workflows, streamline collaboration, and unlock new insights with artificial intelligence (AI), accelerating breakthroughs and advancing precision medicine.

Several recent accomplishments have contributed to Proscia’s momentum, including:


  • Product innovation: The latest release of Concentriq for Research extends the platform’s robust functionality to spatial biology and seamlessly embeds a new version of the AI-powered Automated Quality Control to further improve the quality of data driving R&D. With these updates, the company continues to help users optimize the entire drug discovery and development process on a single platform.
  • Platform growth: Proscia’s users collectively brought 77% more images onto Concentriq for Research in 2022. Along with signaling expanded use of the platform, this growth emphasizes the impact of pathology data in driving major breakthroughs.
  • Active developer community: Half of Proscia’s life sciences customers are now leveraging its developer tools to build custom applications, including computational solutions, and deploy them on Concentriq for Research. An open API enables users to tap into the platform’s extensive interoperability to further drive efficiency and generate new insights.
  • A customer-first experience: To broaden its comprehensive suite of professional services and support offerings, Proscia has introduced a new Rapid Deployment Package and premium support options to help life sciences organizations transition away from legacy solutions and adopt a digital pathology platform with speed and ease.

“We are proud that life sciences organizations pushing the boundaries of science have chosen us to be a part of their journeys,” said David West, CEO of Proscia. “Beyond powering R&D at scale today, Concentriq for Research will enable research teams to capitalize on new opportunities that reimagine the potential of pathology data in advancing how we treat patients for years to come.”

Life sciences organizations are rapidly scaling their adoption of digital pathology and AI to tap into use cases spanning biomarker discovery and quantification, toxicology, and companion diagnostic development. As breakthroughs translate into the clinic, they are generating additional data to fuel the next wave of research innovation.

About Proscia

Proscia is a software company that is accelerating pathology’s digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate discovery, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies rely on Proscia’s software each day. For more information, visit proscia.com.

Share article on social media or email:

Dr. Rod J. Rohrich, Receives Prestigious Award from the American Society of Plastic Surgeons


Dallas Plastic Surgeon Dr. Rod J. Rohrich

Dallas Plastic Surgeon Dr. Rod J. Rohrich

Dr. Rod J. Rohrich, a board certified plastic surgeon in Dallas, Texas and Editor Emeritus of the Journal of Plastic and Reconstructive Surgery (PRS), received the 2022 American Society of Plastic Surgeons’ Presidential Honorary Citation. The American Society of Plastic Surgeons is the largest society of board- certified plastic surgeons in the world. The society President, Dr. Peter Rubin, explained that this award honors individuals that have made significant lifetime landmark contributions to the specialty of plastic surgery.

Dr. Rubin cited that Dr. Rohrich has worked throughout his career in a selfless manner to educate and teach plastic surgeons globally, especially as Editor-in-Chief of PRS, the most respected global peer reviewed plastic surgery journal in the world. Dr. Rohrich is an innovative educator who has trained thousands of plastic surgeons by his lecturing and performing live surgery globally to demonstrate both his expertise in both rhinoplasty and facelift techniques and technology.

His dedication to teaching, giving back and sharing his knowledge with others, is unsurpassed and is the hallmark for how to educate plastic surgeons and other surgical specialists today. With the transition from live interactive meetings to more online webinars and courses, especially during the Covid pandemic, Dr. Rohrich has adapted to and enhanced online teaching to reach an even broader global audience with this new educational technology.

About Rod J. Rohrich, M.D., F.A.C.S.

Dr. Rod J. Rohrich is a board certified plastic surgeon in Dallas, Texas. He is considered one of the most influential surgeons in this century. He was named the top plastic surgeon in America by Newsweek in both rhinoplasty and facelift surgery in 2021 and 2022. Dr. Rohrich is a Clinical Professor of Plastic Surgery at Baylor College of Medicine. He was the first Chair of the Department of Plastic Surgery as well as the first plastic surgeon selected as a Distinguished Teaching Professor at UT Southwestern Medical Center. He graduated from Baylor College of Medicine with high honors, and completed his plastic surgery training at the University of Michigan Medical Center and fellowships at Massachusetts General Hospital/Harvard (hand/microsurgery) and Oxford University (pediatric plastic surgery). He is Chair of the Dallas Rhinoplasty Meeting, Founding Chair of the Dallas Cosmetic Surgery and Medicine Meeting, Founding Member of the Alliance in Reconstructive Surgery, and a Founding Partner of the Dallas Plastic Surgery Institute.

He is the immediate (after serving for 18 years) past Editor-in-Chief of the most respected global peer reviewed plastic surgery journal – the Plastic and Reconstructive Surgery Journal. He is Founding Editor-in-Chief/Editor Emeritus of the first open access peer reviewed plastic surgery journal, PRS Global Open. Dr. Rohrich has published over 1000 peer reviewed articles and seven textbooks in plastic surgery including a best-selling medical book entitled The Facial Danger Zones. Dr. Rohrich recently published an innovative cosmetic surgery video atlas, Cosmetic Surgery by the Masters.

Dr. Rohrich also served as president of the American Society of Plastic Surgeons (ASPS), the largest organization of board certified plastic surgeons in the world. He repeatedly has been selected by his peers as one of America’s best doctors. He received the ASPS Special Achievement Award and on three occasions has received one of his profession’s highest honors, the Plastic Surgery Foundation (PSF) Distinguished Service Award, which recognizes his contributions to education in plastic surgery. In addition, he has been recognized by the PSF with the Plastic Surgery Foundation Distinguished Career Researcher Award for his contributions to plastic surgery research and innovations. He is also the recipient of the ASPS 2022 Honorary Citation.

Share article on social media or email:

Southern Voices Sees Remarkable Accuracy for Their Medical Answering Services After Adopting an Artificial Intelligence Module to Guide Operators


Healthcare AI concept: a digital silhouette of a human face is directed toward an array of medical icons, including a DNA helix, bandage, bone, stomach, needle, and pill.

… [MedMessage Assist] accurately captured over 99% of calls that resulted in a 911 disposition.

Every time a patient calls a practice, their symptoms should be noted fully and addressed in the appropriate window of time. However, this may not always happen when they speak with nonclinical operators (those who man front desks or work at medical call centers) because operators may not recognize important follow-up questions to ask based on the symptoms that are being reported by patients. As a result, the triage nurses or medical providers who receive messages from these operators could then overlook patients who have urgent needs. Now, thanks to TriageLogic’s new module called MedMessage Assist (MMA), operators are already seeing a remarkable difference in the accuracy of their call notes. This includes those taken by operators at Southern Voices, a healthcare telecommunications company.

How MedMessage Assist Helped Southern Voices

When Southern Voices heard about MedMessage Assist, they recognized how valuable it could be, both for their medical call center and for the healthcare providers they represent.

Here was their process prior to implementing this tool: their phone operators would take patient notes during calls and enter them into a nurse triage software, or relay messages to providers. From there, based on the initial messages they received, nurses would categorize them as nonurgent, urgent, or emergent, which dictated how soon they would call patients back.

By implementing MedMessage Assist, Southern Voices has enabled this artificial intelligence-based software to analyze patient complaints as their phone operators take them. Using its real-time analysis, the AI prompts operators with additional clarifying questions to ask patients in order to get accurate descriptions from them.

Results

The results following implementation were illuminating. When reviewing over 1000 calls from one of Southern Voices’ clients where MedMessage Assist was used, the AI module accurately captured over 99% of calls that resulted in a 911 disposition. The AI also indicated urgency for calls that would otherwise have been considered routine. By using MMA, all calls that were potentially life-threatening and urgent were correctly flagged, leading to better response times by nurses.

Training for MedMessage Assist

Because it was designed with all of the necessary prompts to be self-guiding, training on this software is as intuitive as using it. It’s a feature that Jason Miller, President at Southern Voices, was particularly fond of when he told TriageLogic, “We are excited that we can now take more accurate messages without extra training for the staff.”

Regarding Care

While MedMessage Assist is many things, it’s not meant to be a tool for diagnosing patients. Phone operators will continue to follow their normal procedures for medical message intake, with a minimal amount of time added from MMA’s prompts. Triage nurses will then continue to call patients back and use Schmitt-Thompson protocols to determine the best dispositions for care, before referring patients to the appropriate medical providers. MedMessage Assist also applies when operators send messages directly to providers so that on-call doctors can correctly assess the urgency of each complaint before calling a patient back.

HIPAA

Cybersecurity is a priority for TriageLogic and the healthcare tools they develop. Their company has achieved SOC 2 Type 2 compliance, and MedMessage Assist meets the privacy and security requirements under HIPAA.

Try MedMessage

TriageLogic would be delighted to share this tool with any staff interested in improving the accuracy of their medical answering service. Contact them today to discuss a demo, program, or any questions.

About TriageLogic

TriageLogic is a URAC-accredited, physician-led provider of top-quality nurse telehealth technology, remote patient monitoring, and medical call center solutions. Founded in 2007, the TriageLogic Group now serves more than 9,000 physicians and covers over 42 million lives nationwide. Learn more about the company and its services by visiting triagelogic.com.

Share article on social media or email:

New York City and Long Island Gain 4 New Vein Care Clinics


Metro Vein Centers and their team of board-certified vein doctors continue to expand service, offering patients four new locations to access state-of-the-art vein care across New York: Downtown Manhattan, Downtown Brooklyn, Melville, and Port Jefferson Station. Now with 12 nationally accredited vein clinics operating throughout the state, Metro Vein Centers is a clear leader in helping NYC and Long Island residents regain confidence, increase mobility, and enjoy healthy legs.

Regardless of which location you choose, your legs are in good hands. Metro Vein Centers offers a full range of minimally invasive medical and cosmetic vein treatments, including laser vein removal for spider veins, and radiofrequency ablations and injectable medicines such as Varithena® and sclerotherapy for varicose veins.

Chief Medical Officer Dr. Mason Mandy leads a team of fellow board-certified vein doctors at Metro Vein Centers. As he reminds patients every day: “You don’t have to live with pain. Vein treatments are minimally invasive and don’t require long recovery times. We see patients recovering from their pain and regaining mobility. It’s a great feeling.”

Many people don’t realize that varicose vein treatment is considered a medical concern, not merely cosmetic, and therefore it’s usually covered by insurance. The teams at Metro Vein Centers guide patients through the entire treatment process, and coordinate care with healthcare companies — over 200 plans are accepted. The first step is a free vein evaluation for all incoming patients, to look beneath the surface of the skin and investigate leg veins that may be causing uncomfortable symptoms. During their consultation, patients receive a complete diagnostic ultrasound report and a customized care plan catered to their specific needs, symptoms, and concerns.

Learn more about Metro Vein Centers’ new NYC and Long Island vein clinics:

https://www.metroveincenters.com/locations

Call 866-941-2903 today to book your appointment at one of Metro Vein Centers’ 12 New York vein centers.

About Metro Vein Centers

Metro Vein Centers is the fastest-growing vein treatment clinic group in the U.S., with state-of-the-art locations in New York, New Jersey, Michigan, and Connecticut. Our team of board-certified vein doctors are on a mission to provide the best vein treatment experience. Our nationally accredited vein clinics have provided relief to over 100,000 patients suffering from varicose veins, spider veins, and other vein conditions. With 98% patient satisfaction and 3,100+ 5-star reviews, your legs are in great hands.

Share article on social media or email:

Veterinary Virtual Care Association (VVCA) announces new Co-chairs Aaron Smiley, DVM, Chief of Staff at VetCor and Deb Leon, CEO and founder of whiskerDocs


News Image

Together, we will work diligently to provide the animal health communities with much-needed information and analytics, enabling the development and expansion of virtual care delivery models.

Since the VVCA’s inception, Eleanor M. Green, DVM, DACVIM, DABVP, and Audrey Wystrach, DVM, have both dutifully served as Co-chairs on the Board of Directors of the VVCA. With boundless gratitude for their hard work and dedication, we thank Eleanor and Audrey for all they have done for VVCA and all they continue to do for innovation within the veterinary profession. Audrey Wystrach will remain on the Board, while Eleanor M. Green will transition to a Board Emeritus Role while she actively serves as the Veterinary Innovation Council (VIC) President.

The VVCA is excited to welcome founding Board members Aaron Smiley and Deb Leon as its newest Board Co-Chairs. Dr. Smiley is a practicing telemedicine veterinarian in Indiana. He can often be found on social channels sharing his success stories and cases, bringing access to care to his patients (sometimes from the grocery store checkout line). Deb Leon is the founder and CEO of whiskerDocs, a veterinary telehealth platform currently serving over 6 million pets and their pet parents in the US and Canada with 24/7 access to veterinary expertise via phone, email, live chat, and mobile messaging.

“I’m honored to serve the veterinary community through the VVCA to create more opportunities for veterinarians and improve access to care,” said Dr. Smiley in an interview today.

Mrs. Leon added, “It’s my privilege to lead the VVCA Board with Aaron; together, we will work diligently to provide the animal health communities with much-needed information and analytics, enabling the development and expansion of virtual care delivery models. Additionally, we will focus on collaborations with other like-minded organizations, both in North America and internationally.”

About the VVCA: In May 2020, notable leaders in veterinary medicine were confident that it was the perfect time to form an association to support the profession as the COVID pandemic caused incredible challenges and disruption in everyday life and within veterinary practice. The VVCA’s fundamental mission is to make virtual care part of the standard of care in veterinary medicine by advocating best practices, providing educational resources, and creating a space for a broad alliance of professionals to assemble. Today, led by a 15-person Board of cutting-edge experts, the VVCA is growing and evolving to expand its reach and help alleviate access to care issues while bringing a wide range of stakeholders together for tough conversations about how to support and extend the movement of veterinary medicine into the digital age. Find out more at https://vvca.org/.

Share article on social media or email: